EcoDrugPlus

Tyrosine-Protein Kinase Lyn-Like

Ensembl ID : ENSOTSG00005023155
Gene Symbol: LOC112260483
3 Cross references
189 Possible Orthologues:

Tyrosine-Protein Kinase Lyn-Like

Ensembl ID : ENSOTSG00005022166
Gene Symbol: LOC112226929
3 Cross references
189 Possible Orthologues:

Tyrosine-Protein Phosphatase Non-Receptor Type 11

Ensembl ID : ENSOTSG00005022589
Gene Symbol: LOC112219594
3 Cross references
245 Possible Orthologues:

Ubiquitin-Like Protein Fubi

Ensembl ID : ENSOTSG00005031639
Gene Symbol: LOC112217844
3 Cross references
295 Possible Orthologues:

Urotensin 2 Receptor

Ensembl ID : ENSOTSG00005002638
Gene Symbol: UTS2R
1 Cross references
97 Possible Orthologues:

Utrophin

Ensembl ID : ENSOTSG00005030358
Gene Symbol: UTRN
1 Cross references
262 Possible Orthologues:

Utrophin

Ensembl ID : ENSOTSG00005033925
Gene Symbol: UTRN
1 Cross references
262 Possible Orthologues:

V-Akt Murine Thymoma Viral Oncogene Homolog 2

Ensembl ID : ENSOTSG00005038223
Gene Symbol: AKT2
1 Cross references
190 Possible Orthologues:

V-Akt Murine Thymoma Viral Oncogene Homolog 2, Like

Ensembl ID : ENSOTSG00005007284
Gene Symbol: AKT2L
1 Cross references
190 Possible Orthologues:

V-Akt Murine Thymoma Viral Oncogene Homolog 2, Like

Ensembl ID : ENSOTSG00005036386
Gene Symbol: AKT2L
1 Cross references
185 Possible Orthologues:

V-Akt Murine Thymoma Viral Oncogene Homolog 3a

Ensembl ID : ENSOTSG00005006746
Gene Symbol: AKT3A
1 Cross references
203 Possible Orthologues:

V-Rel Avian Reticuloendotheliosis Viral Oncogene Homolog A

Ensembl ID : ENSOTSG00005014269
Gene Symbol: RELA
1 Cross references
194 Possible Orthologues:


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).